Company Description
Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States.
Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology.
Absci Corporation has collaboration agreements with PrecisionLife, Memorial Sloan Kettering Cancer Center, Twist Bioscience, Owkin, Oracle Corporation, and Advanced Micro Devices, Inc. for joint research and development activities.
The company was founded in 2011 and is headquartered in Vancouver, Washington.
| Country | United States |
| Founded | 2011 |
| IPO Date | Jul 22, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 140 |
| CEO | Sean McClain |
Contact Details
Address: 18105 SE Mill Plain Boulevard Vancouver, Washington 98683 United States | |
| Phone | 360 949 1041 |
| Website | absci.com |
Stock Details
| Ticker Symbol | ABSI |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 0001672688 |
| CUSIP Number | 00091E109 |
| ISIN Number | US00091E1091 |
| Employer ID | 85-3383487 |
| SIC Code | 8731 |
Key Executives
| Name | Position |
|---|---|
| Sean McClain | Founder, Chief Executive Officer, President and Director |
| Dr. Zachariah Jonasson Ph.D. | Chief Business Officer and Chief Financial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 22, 2026 | ARS | Filing |
| Apr 22, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 22, 2026 | DEF 14A | Other definitive proxy statements |
| Apr 14, 2026 | SCHEDULE 13D/A | Filing |
| Mar 26, 2026 | SCHEDULE 13D/A | Filing |
| Mar 26, 2026 | SCHEDULE 13G/A | Filing |
| Mar 24, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 24, 2026 | 10-K | Annual Report |
| Mar 24, 2026 | 8-K | Current Report |
| Mar 6, 2026 | 8-K | Current Report |